title: Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI.
abstract: Clostridium difficile infection (CDI) publications have advanced in 2010 at a pace paralleling the increased frequency and severity of clinical infection. Both toxins A and B are essential virulence factors, pcr diagnostic testing is rapid, sensitive and specific, and recurrent CDI can be prevented using monoclonal antibodies to toxins A and B.
authors.affiliation: Edward Hines Jr Veterans Affairs Hospital, 5000 South 5th Avenue, Hines, IL 60141, USA.
authors.forename: Dale N
authors.initials: DN
authors.lastname: Gerding
authors.forename: Stuart
authors.initials: S
authors.lastname: Johnson
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000276:immunology / Q000502:physiology; D001427:Bacterial Toxins / Q000276:immunology; D016360:Clostridioides difficile / Q000235:genetics; D004269:DNA, Bacterial / Q000235:genetics; D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D004768:Enterotoxins / Q000276:immunology / Q000502:physiology; D000077732:Fidaxomicin; D006801:Humans; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D004269:DNA, Bacterial; D004768:Enterotoxins; C041348:tcdA protein, Clostridium difficile; C031815:toxB protein, Clostridium difficile; D000077732:Fidaxomicin